Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2000 1
2002 1
2003 1
2004 2
2005 1
2006 1
2007 1
2008 1
2009 2
2012 2
2013 1
2014 1
2016 1
2017 3
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y, Guo Y, Wu Z, Feng K, Tong C, Wang Y, Dai H, Shi F, Yang Q, Han W. Liu Y, et al. Cytotherapy. 2020 Oct;22(10):573-580. doi: 10.1016/j.jcyt.2020.04.088. Epub 2020 Jun 9. Cytotherapy. 2020. PMID: 32527643 Free article. Clinical Trial.
The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is a rational target in PC. ...The median progression-free survival was 3 month …
The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains poor. Epidermal growth fact …
A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study.
Abdel-Rahman O. Abdel-Rahman O. Int J Colorectal Dis. 2020 May;35(5):911-920. doi: 10.1007/s00384-020-03568-0. Epub 2020 Mar 17. Int J Colorectal Dis. 2020. PMID: 32185469 Review.

Using Kaplan-Meier survival comparison for the three temporal cohorts, the following survival observations were noted: for patients with metastatic esophageal adenocarcinoma: median survival for cohort-1: 8 months, cohort-2: 9 months, cohort-3: 9 months; P < 0.001; for

…
Using Kaplan-Meier survival comparison for the three temporal cohorts, the following survival observations were noted: for patients w …
Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.
Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, Wang S, Guo P, Wu X, Lin Q, Wu H, Huang W, Sun L, Chen H. Pang Y, et al. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1322-1337. doi: 10.1007/s00259-021-05576-w. Epub 2021 Oct 15. Eur J Nucl Med Mol Imaging. 2022. PMID: 34651226
PURPOSE: This study aimed to investigate the diagnostic performance of [(68)Ga]Ga-FAPI PET/CT for primary and metastatic pancreatic carcinoma lesions and compare the results with those of [(18)F]-fluorodeoxyglucose ([(18)F]FDG) PET/CT. ...Compared with CE-CT, …
PURPOSE: This study aimed to investigate the diagnostic performance of [(68)Ga]Ga-FAPI PET/CT for primary and metastatic pancreati …
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R. Hess V, et al. J Clin Oncol. 2003 Jan 1;21(1):66-8. doi: 10.1200/JCO.2003.04.029. J Clin Oncol. 2003. PMID: 12506172 Clinical Trial.
PATIENTS AND METHODS: This multicenter study included patients naive to chemotherapy who had histologically or cytologically confirmed, nonresectable or metastatic pancreatic carcinoma. Gemcitabine was given at a fixed dose of 1,000 mg/m(2) on days 1 and 8 of …
PATIENTS AND METHODS: This multicenter study included patients naive to chemotherapy who had histologically or cytologically confirmed, nonr …
Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status.
Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Mudali SV, et al. Clin Exp Metastasis. 2006;23(7-8):357-65. doi: 10.1007/s10585-006-9045-7. Epub 2006 Dec 5. Clin Exp Metastasis. 2006. PMID: 17146615 Free PMC article.
The expression was predominantly cytoplasmic, although predominant membranous staining was observed in a minority of cases. When evaluated specifically for labeling intensity, primary and metastatic carcinomas were more strongly positive compared to benign ducts and PanIN …
The expression was predominantly cytoplasmic, although predominant membranous staining was observed in a minority of cases. When eval …
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Middleton G, et al. Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259610 Free article. Clinical Trial.
Patients had to have an Eastern Cooperative Oncology Group (ECOG) score of 0-2 and a documented life expectancy of at least 3 months. ...
Patients had to have an Eastern Cooperative Oncology Group (ECOG) score of 0-2 and a documented life expectancy of at least 3 months. …
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Cascinu S, Scartozzi M, Carbonari G, Pierantoni C, Verdecchia L, Mariani C, Squadroni M, Antognoli S, Silva RR, Giampieri R, Berardi R. Cascinu S, et al. Am J Clin Oncol. 2007 Oct;30(5):526-30. doi: 10.1097/COC.0b013e318054675c. Am J Clin Oncol. 2007. PMID: 17921715 Clinical Trial.
METHODS: Forty-four patients with histologically or cytologically verified, locally advanced unresectable and/or metastatic pancreatic carcinoma were eligible for the study. RESULTS: Thirty-three patients (75%) assumed celecoxib for all their treatment period …
METHODS: Forty-four patients with histologically or cytologically verified, locally advanced unresectable and/or metastatic pancre …
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
James E, Waldron-Lynch MG, Saif MW. James E, et al. Anticancer Drugs. 2009 Aug;20(7):634-8. doi: 10.1097/CAD.0b013e32832b511e. Anticancer Drugs. 2009. PMID: 19433978 Review.
Germline mutations in the tumor suppressor genes BRCA1 and BRCA2 have been proven to predict a drastically increased lifetime risk of breast and ovarian cancers in the individuals who carry them. ...Our case is the first clinical piece of evidence that demonstrates an incr …
Germline mutations in the tumor suppressor genes BRCA1 and BRCA2 have been proven to predict a drastically increased lifetime risk of …
CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.
Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z. Li Z, et al. Diagn Pathol. 2014 Apr 8;9:79. doi: 10.1186/1746-1596-9-79. Diagn Pathol. 2014. PMID: 24708709 Free PMC article.
RESULTS: Increased CD44v expression and decreased CD44s expression were found in metastatic pancreatic carcinoma in three different cell lines and in human tumor tissue. ...Multivariate analysis showed that CD44v6+/CD44s- was an independent predictor o …
RESULTS: Increased CD44v expression and decreased CD44s expression were found in metastatic pancreatic carcinoma in thr …
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Colucci G, et al. Cancer. 2002 Feb 15;94(4):902-10. Cancer. 2002. PMID: 11920457 Free article. Clinical Trial.
., total number of patients who achieved complete responses, partial responses, and stable disease) was 42.6% (95%CI, 29-57%) in Arm A and 56.6% (95%CI, 42-70%) in Arm B. A clinical benefit was observed in 21 of 43 patients (49%) in Arm A and in 20 of 38 patients (52.6%) i …
., total number of patients who achieved complete responses, partial responses, and stable disease) was 42.6% (95%CI, 29-57%) in Arm A and 5 …
22 results